(Q36075879)

English

Multicenter, Double-Blind, Randomized, Phase 2 Study Evaluating the Novel Antibiotic Cadazolid in Patients with Clostridium difficile Infection.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

12 August 2017

Multicenter, Double-Blind, Randomized, Phase 2 Study Evaluating the Novel Antibiotic Cadazolid in Patients with Clostridium difficile Infection. (English)

1 reference

Europe PubMed Central

12 August 2017

multicenter clinical trial

0 references

Clostridium difficile

0 references

0 references

5

object named as

Dale N Gerding

1 reference

Europe PubMed Central

12 August 2017

Oliver A Cornely

9

object named as

Oliver A Cornely

1 reference

Europe PubMed Central

12 August 2017

author name string

Thomas Louie

1

1 reference

Europe PubMed Central

12 August 2017

Carl Erik Nord

2

1 reference

Europe PubMed Central

12 August 2017

George H Talbot

3

1 reference

Europe PubMed Central

12 August 2017

Mark Wilcox

4

1 reference

Europe PubMed Central

12 August 2017

Martha Buitrago

6

1 reference

Europe PubMed Central

12 August 2017

Hilke Kracker

7

1 reference

Europe PubMed Central

12 August 2017

Pascal Charef

8

1 reference

Europe PubMed Central

12 August 2017

language of work or name

0 references

publication date

27 July 2015

1 reference

Europe PubMed Central

12 August 2017

number of pages

8

1 reference

based on heuristic

inferred from page(s)

Antimicrobial Agents and Chemotherapy

1 reference

Europe PubMed Central

12 August 2017

59

1 reference

Europe PubMed Central

12 August 2017

6266-6273

1 reference

Europe PubMed Central

12 August 2017

10

1 reference

Europe PubMed Central

12 August 2017

Susceptibility of Clostridium difficile isolates from a Phase 2 clinical trial of cadazolid and vancomycin in C. difficile infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4576054

2 October 2017

Investigations of the mode of action and resistance development of cadazolid, a new antibiotic for treatment of Clostridium difficile infections

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4576054

2 October 2017

In vitro and in vivo antibacterial evaluation of cadazolid, a new antibiotic for treatment of Clostridium difficile infections

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4576054

2 October 2017

Fidaxomicin versus vancomycin for Clostridium difficile infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4576054

2 October 2017

Clostridium difficile infection: epidemiology, risk factors and management

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4576054

2 October 2017

Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4576054

2 October 2017

Clostridium difficile infection: new developments in epidemiology and pathogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4576054

2 October 2017

Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4576054

2 October 2017

Clostridium difficile--more difficult than ever

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4576054

2 October 2017

Clostridium difficile: changing epidemiology and new treatment options

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4576054

2 October 2017

Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4576054

2 October 2017

An epidemic, toxin gene-variant strain of Clostridium difficile

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4576054

2 October 2017

Alternative treatments for Clostridium difficile disease: what really works?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4576054

2 October 2017

Stool form scale as a useful guide to intestinal transit time

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4576054

2 October 2017

Cadazolid, a novel antibiotic with potent activity against Clostridium difficile: safety, tolerability and pharmacokinetics in healthy subjects following single and multiple oral doses.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4576054

23 September 2018

In vitro activity of cadazolid against Clostridium difficile strains isolated from primary and recurrent infections in Stockholm, Sweden

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4576054

23 September 2018

Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4576054

23 September 2018

Costs of nosocomial Clostridium difficile-associated diarrhoea

1 reference

https://pubmed.ncbi.nlm.nih.gov/26248357

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/26248357

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1128/AAC.00504-15

1 reference

Europe PubMed Central

12 August 2017

1 reference

Europe PubMed Central

12 August 2017

1 reference

Europe PubMed Central

12 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36075879&oldid=1811201991"